TargetBeta
HTR2A
5-hydroxytryptamine receptor 2A · also 5-HT2A, HTR2 · 5-hydroxytryptamine receptors, G protein-coupled
13 programs in company-led studies act on HTR2A, from 9 companies: 3 in phase 3, 8 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| iloperidonerule | Vanda Pharmaceuticals | phase 4 | 153 running | DRD2 | ChEMBL |
| Aripiprazolerule | Otsuka | phase 4 | 1312 running | DRD2, HTR1A | ChEMBL |
| lurasidonerule | Sumitomo Pharma | phase 4 | 522 running | DRD2 | ChEMBL |
| cyclobenzaprinerule | Tonix Pharmaceuticals | phase 4 | 322 running | HTR2C | ChEMBL |
| Risperidonerule | Johnson & Johnson | phase 4 | 1111 running | DRD2, HTR2C | ChEMBL |
| paliperidonerule | Johnson & Johnson | phase 4 | 1061 running | DRD2 | ChEMBL |
| Olanzapinerule | Eli Lilly | phase 4 | 761 running | DRD2, DRD3, DRD4, HTR2C | ChEMBL |
| brexpiprazolerule | Otsuka | phase 4 | 700 running | DRD2, HTR1A | ChEMBL |
| Psilocybinrule | COMPASS Pathways | phase 3 | 2210 running | – | ChEMBL |
| lumateperonerule | Johnson & Johnson | phase 3 | 256 running | DRD2, SLC6A4 | ChEMBL |
| Trazodonerule | Angelini Pharma | phase 3 | 140 running | HTR2C, SLC6A4 | ChEMBL |
| bretisilocin | AbbVie | phase 2 | 10 running | – | the company's pipeline |
| bretisilocin | AbbVie | phase 1 | 10 running | – | the company's pipeline |
Conditions their studies are in
- Depressive Disorder, Major, 8 programs
- Schizophrenia, 8 programs
- Bipolar Disorder, 6 programs
- Stress Disorders, Post-Traumatic, 3 programs
- Alzheimer Disease, 2 programs
- Autistic Disorder, 2 programs
- Depression, 2 programs
- Depressive Disorder, Treatment-Resistant, 2 programs
- Psychotic Disorders, 2 programs
- Adjustment Disorders, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Psilocybin · COMPASS Pathways · phase 3 · NCT06608459
- Dec 31, 2026paliperidone · Johnson & Johnson · phase 4 · NCT07493551
- Apr 5, 2027lumateperone · Johnson & Johnson · phase 3 · NCT05850689
- Sep 5, 2027Aripiprazole · Otsuka · phase 4 · NCT07547384
- Oct 2027lurasidone · Sumitomo Pharma · phase 4 · NCT07781293
- Nov 2027iloperidone · Vanda Pharmaceuticals · phase 4 · NCT06961968
- Dec 2027Risperidone · Johnson & Johnson · phase 4 · NCT07565428
- Dec 2027Olanzapine · Eli Lilly · phase 4 · NCT07565428
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.